CTIS2024-511526-31-00进行中（未招募）1 期
01API2024
Celon Pharma S.A.0 个研究点目标入组 38 人开始时间: 2024年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to learn if UCB3101 is safe and how it moves through the body of healthy participantsHealthy ParticipantsMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848CTIS2023-504586-24-00CB Biopharma88
进行中（未招募）
1 期
A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate CancerAdult subjects with de novo or treatment-emergent neuroendocrine prostate cancerMedDRA version: 22.1Level: PTClassification code: 10082915Term: Neuroendocrine carcinoma of prostate Class: 100000004864CTIS2024-513316-10-00Amgen Inc.35
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.CTIS2024-512773-27-00Sun Pharmaceutical Industries Limited54
进行中（未招募）
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872CTIS2023-503968-16-00Bayer Consumer Care AG16
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteersPrevention of atherothrombotic events in adult patients with- acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventMedDRA version: 20.0Level: PTClassification code: 10028596Term: Myocardial infarction Class: 100000004849CTIS2023-504116-14-00Celon Pharma S.A.40